"Use of checkpoint inhibitors in gray zone lymphoma" by Yensy Mariana Zelaya Rosales, Juliene Lima Mesquita et al.

Article Title

Use of checkpoint inhibitors in gray zone lymphoma

Authors

Yensy Mariana Zelaya Rosales, Universidade Federal do Ceara´, Fortaleza, Ceara´, BrazilFollow
Juliene Lima Mesquita, Universidade Federal do Ceara´, Fortaleza, Ceara´, Brazil
Yhasmine Delles Oliveira Garcia, Universidade Federal do Ceara´, Fortaleza, Ceara´, Brazil
Fernando Ricardo Fernandes Paz, Hospital Universitario Walter Cantidio, Fortaleza, Ceara´, Brazil
Naiana Castelo Branco Campos, Universidade Estadual do Maranha˜o (UEMA), Sa˜o Luis, Maranha˜o, Brazil
Joa˜o Paulo de Vasconcelos Leita˜o, Central de Analises Clinicas (CAC), Fortaleza, Ceara´, Brazil
Francisco Da´rio Rocha Filho, Central de Analises Clinicas (CAC), Fortaleza, Ceara´, Brazil
Ricardo Vale Albino Oliveira Filho, Omnimagem, Fortaleza, Ceara´, Brazil
Rome´lia Pinheiro Gonc¸alves Lemes, Universidade Federal do Ceara´, Fortaleza, Ceara´, Brazil
Fernando Barroso Duarte, Department of Surgery, Universidade Federal do Ceara´, Fortaleza, Ceara´, Brazil

Abstract

Checkpoint inhibitors, cancer immunotherapies, are the new forms of treatment for gray zone lymphoma, a rare subtype that combines the characteristics of both Hodgkin and non-Hodgkin disease forms. Programmed cell death protein 1/programmed cell death ligand 1 (PD-L1/PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) modulate the immune system function. Immunological checkpoints can be stimulatory or inhibitory, and tumors can use these checkpoints to protect against immune system attacks. This is a case report of a difficult diagnosis and describes the most current treatment using checkpoint inhibitors, through the review of the clinical record of a patient diagnosed with gray area lymphoma in August 2019, using a descriptive and cross-sectional analysis of the clinical history and disease evolution. The case showed that pembrolizumab therapy is an effective treatment option for patients with rare gray zone lymphoma refractory to different lines of treatment. Both the diagnosis and treatment of gray area lymphoma remain a challenge for the medical and multiprofessional teams,and collaboration between them ensured effective treatment for the patient.

Recommended Citation

Rosales, Yensy Mariana Zelaya; Mesquita, Juliene Lima; Garcia, Yhasmine Delles Oliveira; Paz, Fernando Ricardo Fernandes; Campos, Naiana Castelo Branco; Leita˜o, Joa˜o Paulo de Vasconcelos; Filho, Francisco Da´rio Rocha; Filho, Ricardo Vale Albino Oliveira; Lemes, Rome´lia Pinheiro Gonc¸alves; and Duarte, Fernando Barroso (2023) "Use of checkpoint inhibitors in gray zone lymphoma," Hematology/Oncology and Stem Cell Therapy: Vol. 16 : Iss. 1 , Article 9.
Available at: https://doi.org/10.1016/j.hemonc.2020.06.001